Nuvalent
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 92
- Market Cap
- $5.4B
- Website
- http://www.nuvalent.com
- Introduction
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC
- Conditions
- Non Small Cell Lung CancerALK-positive Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Nuvalent Inc.
- Registration Number
- NCT06834074
- Locations
- 🇨🇭
Kantonsspital Luzern, Lucerne, Switzerland
🇫🇷GCS IUCT Oncopole, Toulouse, Occitanie, France
🇫🇷Institut Gustave Roussy, Villejuif, Île-de-France, France
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC (NVL-520-EAP)
- Conditions
- Non Small Cell Lung CancerROS1-positive Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Nuvalent Inc.
- Registration Number
- NCT06797362
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, Auvergne-Rhône-Alpes, France
🇳🇱University Medical Center Groningen, Groningen, Netherlands
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Conditions
- Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
- Interventions
- Drug: Neladalkib (NVL-655)
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06765109
- Locations
- 🇺🇸
Washington University Center for Advanced Medicine, Saint Louis, Missouri, United States
🇺🇸Clinical Research Alliance Inc., New Hyde Park, New York, United States
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06521554
- Locations
- 🇺🇸
City of Hope - Lennar, Irvine, California, United States
🇺🇸OSU Brain and Spine Hospital, Columbus, Ohio, United States
🇦🇺North Shore Health Hub, Saint Leonards, New South Wales, Australia
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 470
- Registration Number
- NCT05384626
- Locations
- 🇩🇪
Universitatsklinikum Koln - University Hospital Cologne, Cologne, Germany
🇩🇪Universkitatsklinikum Heidelberg - University Hospital Heidelberg, Heidelberg, Germany
🇯🇵Okayama University Hospital, Okayama, Japan
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Conditions
- Metastatic Solid TumorLocally Advanced Solid Tumor
- Interventions
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 359
- Registration Number
- NCT05118789
- Locations
- 🇺🇸
UCI Medical Center, Orange, California, United States
🇺🇸Stanford Medicine, Palo Alto, California, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States